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Platelet endothelial cell adhesion molecule-1 (PECAM-1) inhibits platelet response to collagen and
may also inhibit two other major platelet agonists ADP and thrombin although this has been less
well explored. We hypothesized that the combined effect of inhibiting these three platelet activating
pathways may act to signiﬁcantly inhibit thrombus formation. We demonstrate a negative relation-
ship between PECAM-1 surface expression and platelet response to cross-linked collagen related
peptide (CRP-XL) and ADP, and an inhibitory effect of PECAM-1 clustering on platelet response to
CRP-XL, ADP and thrombin. This combined inhibition of multiple signaling pathways results in a
marked reduction in thrombus formation.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction collagen [16] and increased thrombus formation [17] have been re-Platelet endothelial cell adhesion molecule-1 (PECAM-1, CD31),
an immunoreceptor tyrosine-based inhibitory motif (ITIM) con-
taining protein plays a largely activatory role regulating integrin
activation in leukocytes and endothelial cells [1–5]. It is also ex-
pressed at high levels on platelets (5000–20 000 copies per cell
[6]) where, upon homophilic ligation or following stimulation with
collagen or thrombin, it becomes tyrosine phosphorylated (Tyr663
and Tyr686) by Src-family kinases [7–10] facilitating the binding
of Src-homology 2 domain-containing signaling proteins [8,11].
Reports of the role of PECAM-1 in platelets have been inconsis-
tent. Initially characterized as co-stimulatory for ADP-mediated
platelet activation [12], we and others have shown that clustering
or ligation of PECAM-1 inhibits signaling downstream of collagen
thereby inhibiting platelet aggregation and thrombus formation
in vitro [13,14]. While these effects have been consistently demon-
strated, their magnitude is modest [15] and might be considered
mechanisms for ﬁne tuning platelet reactivity.
Reports of PECAM-1 deﬁcient mouse platelets are also complex
and differ depending on the agonist used. Hyper-responsiveness toal Societies. Published by Elsevier
.ported while aggregation in response to PAR-4 stimulation or ADP
remains unaltered, as does static adhesion [18]. Furthermore im-
paired outside-in signaling through aIIbb3 has been demonstrated
in knock-out mice [18], which, together with the known role of PE-
CAM-1 in the up regulation of integrin activity in leukocytes and
endothelial cells, suggests that platelet PECAM-1 may act posi-
tively to enhance integrin mediated outside-in signaling.
In this study we demonstrate, in humans, a negative relation-
ship between the surface expression of PECAM-1 and variation in
platelet response to stimulation with cross-linked collagen related
peptide (CRP-XL) and ADP, and an inhibitory effect of PECAM-1
receptor clustering on platelet response to CRP-XL, ADP and throm-
bin. The combined effect of this small but signiﬁcant inhibition of
multiple agonist stimulation pathways is a more marked reduction
in thrombus formation.
2. Materials and methods
2.1. Ethics
Eighty-nine healthy subjects were recruited, to study the asso-
ciation between PECAM-1 expression and platelet function from
the National Health Service Blood and Transplant blood donorB.V. Open access under CC BY-NC-ND license.
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study was approved by the Huntingdon Research Ethics Commit-
tee. Blood from all other subjects was taken after informed written
consent approved by the University of Reading Research Ethics
Committee.
2.2. Reagents
CRP-XL (monomeric sequence GCI[GPO]10GCOG) was prepared
as described previously [19], thrombin and ADP were from Sigma
Chemical Co. Ltd. (Poole, Dorset, UK). Thrombin receptor activation
peptide (TRAP, SFLLRN) was from Bachem (St. Helens, UK). Where
indicated, speciﬁc inhibitors of subsidiary activation pathways
where added to ensure pathway speciﬁc responses weremeasured;
indomethacin, apyrase, and hirudin (Sigma). Gly-pro-arg-pro pep-
tide (GPRP) (Sigma) was addedwhere thrombinwas present to pre-
vent clotting. PECAM-1 monoclonal antibody (mAb) AB468 and
appropriate isotype control AB600 (Autogen Bioclear, Wilts, UK)
were dialyzed to remove azide. mAb IV.3 was puriﬁed from hybrid-
oma cell culture medium and F(ab0) fragments generated using the
Fab Preparation Kit (Thermo Fisher Scientiﬁc, Northumberland, UK).
Digestionof the F(ab0) fragmentswere conﬁrmedby separating frag-
ments by SDS–PAGE under reducing condition and visualized using
Coomassie stain. Efﬁcacy of the F(ab0) was determined by it’s ability
to block activation of the low-afﬁnity IgG receptor FccRIIA by cross-
linked whole mAb IV.3. PE/Cy5-CD62P was from BD Biosciences
(Oxford, UK), and ﬁbrinogen was from Sigma and FITC labeled in
house. FITC-anti-ﬁbrinogen (Dako Ltd., Ely, UK) or PE-anti-CD62P
(Bristol Institute for Transfusion Science, Bristol, UK). Hepes buf-
fered saline (HBS; 0.14 M NaCl, 5 mM KCl, 1 mM MgSO4, 10 mM
HEPES (sodium salt), pH7.4) was used for all dilutions.
2.3. Blood collection
Blood was drawn from the antecubital fossa vein via a 21-gauge
butterﬂy needle and a vacuette tube (Greiner Bio-One, Stonehouse,
UK), and was used within 10 min of donation. The ﬁrst 3 mL of
blood were discarded and subsequent samples were taken into
0.105 M sodium citrate.
2.4. PECAM-1 cross-linking
PECAM-1 cross-linking was performed prior to platelet stimula-
tion as follows. Platelets, in citrated whole blood or platelet rich
plasma (PRP), were incubated with a saturating concentration of
anti-PECAM-1 or isotype control (10 lg/mL) for 10 min followed
by an excess of cross-linking antibody, goat-anti-mouse IgG anti-
body (20 lg/mL, Sigma) for 10 min.
2.5. Calcium ﬂux [Ca2+]i
Indomethacin (10 lM), hirudin (10 U/mL) (not thrombin stimu-
lated samples), apyrase (4 U/mL) (not ADP stimulated samples)
and GPRP (0.5 mg/mL) (thrombin stimulated samples only) were
added to PRP with an equal volume of HBS containing Fluo-4
NW dye (Molecular Probes, Paisley, UK) and probenecid (2.5 mM)
and incubated at 37 C for 30 min. Platelets were stimulated with
ADP (105M), thrombin (1U/mL) or CRP-XL (5 lg/mL). [Ca2+]i was
measured using a Fluoroskan Ascent plate reader (Thermo Labsys-
tems, Basingstoke, UK) with excitation at 485 nm, and emission
measured at 538 nm.
2.6. Flow cytometry
Whole blood ﬂow cytometry was carried out as previously de-
scribed [20]. Brieﬂy, citrated whole blood was added to HBS con-taining pathway speciﬁc inhibitors as appropriate (described
above). Samples were incubated for 20 min at room temperature
with either CRP-XL, thrombin, ADP, or TRAP, and FITC-labeled
ﬁbrinogen (in excess) and PE/Cy5-anti-CD62P. Reactions were
stopped by 100-fold dilution in 0.2% formyl saline. Data for 5000
platelets were recorded as percentage of cells positive for the acti-
vation marker.
2.7. Association between PECAM-1 expression and platelet function
Platelet reactivity was analyzed by whole blood ﬂow cytometry
in 89 healthy blood donors taken from the Bloodomics Platelet
Functional Cohort, as described previously [20]. Platelets were
stimulated, in the presence of pathway speciﬁc inhibitors as appro-
priate (described above), with ADP (107 M), TRAP (2  106 M)
and CRP-XL (0.1 lg/mL) and binding of FITC-anti-ﬁbrinogen and
PE-anti-CD62P were measured by ﬂow cytometry. To measure
the surface expression of PECAM-1 (mouse CD31 mAb (Serotec,
Oxford, UK)), aIIbb3 (RFGP56, A.H. Goodall, University of Leicester),
GPVI (HY101, M.L. Kahn, University of Pennsylvannia) and GPIa
(15D7, H. Deckmyn, Katholieke Universiteit Leuven), antibodies
were incubated with PRP for 30 min. Platelets were then washed,
incubated with FITC-goat-anti-mouse secondary antibody (Dako,
Ely, UK) for 30 min, and analyzed by ﬂow cytometry.
2.8. Thrombus formation in vitro
Thrombus formation in citrated whole blood under arterial ﬂow
conditions was performed as previously described [21,22]. Brieﬂy,
whole blood loaded with 3,30-dihexyloxacarbocyanine iodide was
perfused through collagen coated (100 lg/mL) glass micro-capil-
laries (shear rate = 1000 s1), followed by Tyrodes–Hepes buffer.
Images were captured at 2 lm intervals in the Z-plane within ﬁve
randomly-selected ﬁelds of view. Thrombi were then visualized
using a Leica DMIRE2 inverted confocal microscope (using
NPLANL20_/0.4 objective lens with 0- to 2-mm correction). Throm-
bus volume calculated from Z-series images captured and analyzed
using TCS SP2 software (Leica). Protein was subsequently eluted
from the slides by perfusion with 200 lL Tris-buffered saline con-
taining NP40 (1% vol/vol) and quantiﬁed using the BCA Protein as-
say (Thermo Fisher Scientiﬁc, Cramlington, UK).
2.9. Statistics
PECAM-1 cross-linking modulation of platelet response was
analyzed by repeat measure ANOVA. Paired t-test was used to ana-
lyse the peak value, ﬁnal value and total (area under the curve)
[Ca2+]i. The association between PECAM-1 surface expression and
platelet response was tested using linear regression. All analysis
was carried out using SPSS version 15 (SPSS Inc., Chicago, USA).3. Results
The inhibition, by PECAM-1, of platelet response to GPVI stimu-
lation, has been demonstrated by us and others [13,14], although
some debate surrounds the issue of whether PECAM-1 modulates
signaling stimulated by other platelet agonists. We therefore ex-
plored this in more detail by measuring platelet reactivity to path-
way speciﬁc activation by CRP-XL, thrombin and ADP in the
presence of cross-linked anti-PECAM-1 antibody which we have
previously shown to cause PECAM-1 phosphorylation [13], or iso-
type control. Following PECAM-1 cross-linking total platelet
[Ca2+]i reduced by 7.5 ± 2.0% in response to CRP-XL, and
11.2 ± 3.3% in response to thrombi. Similarly, peak [Ca2+]i was re-
duced by 6.2 ± 2.2% and 10.0 ± 2.8%, and ﬁnal [Ca2+]i reduced by
3620 C.I. Jones et al. / FEBS Letters 583 (2009) 3618–36248.8 ± 1.3% and 14.9 ± 4.0%, respectively (P < 0.05, in all cases). Nei-
ther total nor peak [Ca2+]i in response to ADP were affected by PE-
CAM-1 cross-linking (Fig. 1a). PECAM-1 cross-linking did not
initiate [Ca2+]i in the absence of agonist (data not shown). Further-
more PECAM-1 cross-linking, across a range of CRP-XL concentra-Fig. 1. Inhibitory effect of PECAM-1 cross-linking on platelet function. (A) [Ca2+]i in re
control (solid line) cross-linking (mean of four individuals). (B) P-selectin expression and
1 antibody (open circles) and the isotype control (full circles) cross-linking. All points are
curves over the entire concentration range. (D) Representative ﬂow cytometry histogram
stimulation following anti-PECAM-1 antibody (black line) and the isotype control (graytions inhibited P-selectin exposure by 11.2% (range: 2.7–20.8%,
P = 0.036) and ﬁbrinogen binding to aIIbb3 by 9.9% (range: 3.3–
17.4%, P = 0.046) (Fig. 1B and C). Similar magnitudes of inhibition
were seen in response to both thrombin and ADP (Fig. 1B and C).
The mean inhibition of P-selectin exposure in response tosponse to agonists following anti-PECAM-1 antibody (dotted line) and the isotype
(C) ﬁbrinogen binding to platelets in response to stimulation following anti-PECAM-
the mean ± S.E. of ﬁve individuals. P-values compare the difference between the two
s showing P-selectin expression and ﬁbrinogen binding to platelets in response to
line) cross-linking.
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ADP was 14.9% (range: 3.9–22.7%, P = 0.013). Fibrinogen binding
was inhibited by 9.3% (range: 6.1–16.1%, P = 0.024) in response to
thrombin and 10.7% (range: 2.8–24.4%, P = 0.035) in response to
ADP.
The inhibitory effect seen here was speciﬁc for cross-linked
anti-PECAM-1 antibody. The level of stimulation achieved in the
presence of the cross-linked isotype control was not signiﬁcantly
different to that seen in the absence of antibodies (data not shown)
and no other combination of antibodies, apart from cross-linked
anti-PECAM-1 antibody, caused any signiﬁcant change to platelet
activation (Fig. 2). Platelet response was not inhibited if incubated
with the PECAM-1 antibody and F(ab0) fragments of the cross-link-
ing antibody (Fig. 2). Furthermore, pre-incubation with IV.3 F(ab0)
fragments, to block the low-afﬁnity receptor for IgG FccRIIA, did
not alter the inhibitory effect of PECAM-1 cross-linking (Fig. 2).
Therefore the inhibition of platelet reactivity by PECAM-1 is not
a generic antibody effect. As with [Ca2+]i no combination of anti-
bodies caused any platelet activation in the absence of agonists
(data not shown).
If PECAM-1 function is important for the regulation of platelet
function, variation in the surface expression of the protein should
impact on platelet reactivity. To test this we examined the rela-
tionship between surface expression of PECAM-1 on unactivated
platelets and its association with P-selectin exposure and ﬁbrino-
gen binding to platelets in response to CRP-XL, ADP and TRAP, in
89 healthy subjects [20]. Surface expression of PECAM-1 was neg-
atively correlated with P-selectin expression and ﬁbrinogen bind-Fig. 2. Inhibitory effect of PECAM-1 is not a generic antibody effect. (A and C) P-selectin e
only inhibited by cross-linking anti-PECAM-1 antibodies, and (A and B) not with any oth
and D) F(ab0) of the cross-linking antibody. Nor (C and D) was this inhibition attenuated
presence of appropriate agonists. (C and D) No inhibitors were used. All bars are the m
between the samples incubated with cross-linked anti-PECAM-1 and all other points.ing in response to CRP-XL (P = 0.009 and 0.003, respectively) and
ADP (P = 0.017 and 0.003, respectively) although not to TRAP
(Table 1). While the strength of this association is modest, account-
ing for between 6% and 10% of the variation in platelet response to
CRP-XL and ADP, it was of a similar magnitude to the positive asso-
ciation seen between platelet reactivity and GPVI or aIIbb3 surface
expression. Associations of this magnitude are entirely expected in
this context given that platelet activation is a multi-factorial pro-
cess requiring the integration of multiple signaling steps. Variation
in any of these steps will have a moderate impact on the ﬁnal level
of response. It is important here to separate out the information
being given by the r2 value and the P-value. r2 is the proportion
of variation in platelet function explained by the regression model
and gives information about the strength of the association, while
the P-value gives information on whether that association is likely
to have occurred by chance. Therefore given an appropriate sample
size it is entirely possible, as is the case here, to identify weak asso-
ciations that are statistically signiﬁcant. The negative association
identiﬁed here conﬁrms our ﬁndings of an inhibitory role for PE-
CAM-1 in CRP-XL and ADP induced platelet activation.
There is a clear dichotomy in these results. While PECAM-1
cross-linking inhibited platelet response to thrombin (Fig. 1), PE-
CAM-1 expression showed no relationship with platelet activation
following stimulation by TRAP in the association studies (Table 1).
Subsequent investigation established that PECAM-1 cross-linking
did not inhibit either ﬁbrinogen binding or P-selectin expression
in response to TRAP (Fig. 3). These results support the ﬁndings of
the association study, however, a discrepancy remains betweenxpression and (B and D) ﬁbrinogen binding to platelets in response to stimulation is
er combination of the anti-PECAM-1, isotype control, cross-linking antibodies or (C
by pre-incubation with IV.3 F(ab0) fragments. (A and B) stimulation occurred in the
ean ± S.E. of four individuals. *P < 0.05, **P < 0.01. P-values compare the difference
Fig. 3. Inhibitory effect of PECAM-1 cross-linking does not reduce TRAP induced platelet activation. P-selectin exposure and ﬁbrinogen binding to platelets in response to
TRAP (comparing the entire concentration range, P = 0.566 and 0.489, respectively). Cross-linked anti-PECAM-1 antibody (open circles) and the isotype control (full circles).
All data are given as the mean ± S.E. of four individuals.
Table 1
Association between PECAM-1 surface expression and platelet reactivity. The linear regression analysis showing the association (positive (bold) and negative (bold italic))
between surface expression of four platelet surface molecules and platelet reactivity. In line with previous reports surface expression of GPVI is positively associated with platelet
response to CRP-XL [25] accounting for approximately 20% of the variation in platelet response to this agonist. Surface expression of aIIbb3 was also positively correlated with
platelet ﬁbrinogen binding in response to ADP and TRAP. Surface expression of PECAM-1 showed a negative association with both ﬁbrinogen binding and P-selectin expression in
response to CRP-XL and ADP. GPVI and aIIbb3 expression were included as confounding variables where indicated. As previously reported time of day was found to affect platelet
response to CRP-XL in this study and was included, where indicated, as a confounding factor [20]. Mean platelet volume was strongly correlated with PECAM-1 expression
(P = 0.00003, r2 = 0.18) and was also included as a confounding variable as indicated.
Agonist Measured response Percentage of positive
platelets. Median (min–max)
Platelet surfaces molecules
GPVI aIIbb3 PECAM-1 Gpla
Receptor surface expression. Median ﬂuorescence intensity (U). Median (min–max)
12.0 (5.2–24.9 172.5 (56.1–272.9) 31.5 (11.7–49.0) 16.5 (7.0–27.0)
r2 P-value r2 P-value r2 P-value r2 P-value
CRP-XL (0.1 lg/mL) Fibrinogen binding 39.0% (3.2–78.2) 0.200a 0.00001a 0.001a,b 0.74a,b 0.097a,b,d 0.003a,b,d 0.003a,b 0.595a,b
P-selectin expression 56.0% (3.9–90.7) 0.211a 0.000005a 0.0004a,b 0.847a,b 0.075a,b,d 0.009a,b,d 0.007a,b 0.431a,b
ADP (1  107 M) Fibrinogen binding 26.5% (2.4–73.7) 0.021 0.178 0.061 0.02 0.094c,d 0.003c,d 0.005c 0.511c
P-selectin expression 11.3% (5.2–26.7) 0.012 0.306 0.016 0.245 0.064d 0.017d 0.019 0.205
TRAP (2  106 M) Fibrinogen binding 12.2% (2.1–68.8) 0.042 0.053 0.051 0.034 0.024d 0.148c,d 0.023c 0.161c
P-selectin expression 20.8% (6.3–62.0) 0.015 0.251 0.015 0.25 0.005d 0.519d 0.02 0.191
Confounding variables:
a Times of day.
b GPVI surface expression.
c aIIbb3 surface expression.
d Mean platelet volume.
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lets and its lack of effect on TRAP stimulation. This may stem from
the involvement of glycoprotein (GP) Iba in thrombin [23] but not
TRAP (which is PAR-1 speciﬁc) induced platelet activation and may
indicate a role for PECAM-1 in mediating the action of GPIba dur-
ing thrombin stimulation of platelets. PECAM-1 has previously
been shown to be involved in GPIba mediated activation of plate-
lets, becoming tyrosine phosphorylated upon vWF binding to GPI-
ba, and PECAM-1 deﬁcient mice show enhanced aggregation in
response to vWF [24]. Thus it is not inconceivable that stimulation
of PECAM-1 inhibits the action of GPIba causing reduced thrombin
induced platelet activation.
During thrombus formation platelets are exposed to a variety of
stimuli simultaneously, including collagen, thrombin and ADP. It is,
therefore, possible that the small inhibitory effects in multiple
pathways, that we have described so far, interact resulting in a
greater inhibition of platelet response and thrombus formation.
This could be seen in the ﬂow cytometry assay when comparing
the response of platelets to CRP-XL in the presence and absence
of inhibitors of endogenous thrombin, ADP, and thromboxane. PE-
CAM-1 cross-linking had a greater inhibitory effect on CRP-XL
(0.1 lg/mL) stimulation in the absence of hirudin, apyrase andindomethacin, thereby allowing secondary activation pathways
to play a role, than in the presence of these inhibitors; ﬁbrinogen
binding was reduced by 15.5 ± 2.7% compared to 4.9 ± 2.8%,
P = 0.002, and P-selectin expression was reduced by 15.5 ± 1.8%
compared to 6.2 ± 4.9%, P = 0.01, respectively (Fig. 4). A similar in-
crease in inhibition was seen when comparing the effect of PE-
CAM-1 cross-linking on platelets stimulated with CRP-XL (1 lg/
mL) in the presence of inhibitors or CRP-XL (0.1 lg/mL) in their ab-
sence. While both treatments gave comparable levels of platelet
activation with the isotype control, the level of inhibition resulting
from PECAM-1 cross-linking was signiﬁcantly greater in the ab-
sence of inhibitors (Fig. 4).
To identify the magnitude of the inhibitory effect of PECAM-1 in
conditions that are more reﬂective of in vivo processes, thrombi
were formed under arterial ﬂow conditions in collagen coated mi-
cro-capillary slides. Following PECAM-1 cross-linking total throm-
bus volume was reduced by 49.8 ± 9.9% (P = 0.002) compared to
treatment with the isotype control, and the area of the glass capil-
lary covered by thrombi was similarly reduced by 54.1 ± 7.9%
(P = 0.0005) (Fig. 5). The total amount of protein eluted from the
slides following thrombus formation also decreased in the pres-
ence of cross-linked PECAM-1 by 16.9 ± 4.3% (Fig. 5D).
Fig. 4. The inhibitory effects of PECAM-1 on multiple activation pathways interact to enhance the inhibition of platelet activation. (A and B) P-selectin exposure and
ﬁbrinogen binding to platelets in response to CRP-XL in the presence or absence of inhibitors of endogenous thrombin, ADP, and thromboxane. P-values compare cross-linked
anti-PECAM-1 antibody (gray bar) and the isotype control (black bar) treated samples. (C and D) Inhibition of platelet response following PECAM-1 cross-linking. P-values
compare the level of inhibition in the absence of inhibitors with that seen in their presence. All data are given as the mean ± S.E. of four individuals. *P < 0.05, **P < 0.005,
***P < 0.0005.
Fig. 5. Inhibitory effect of PECAM-1 cross-linking on thrombus formation. (A and B) Representative images showing thrombus formation on collagen coated slides following
cross-linking of the isotype control or anti-PECAM-1 antibodies, respectively. (C) Mean volume, (D) the total amount of protein eluted from the slides, and (E) coverage
following thrombus formation following anti-PECAM-1 antibody or isotype control cross-linking. To correct for inter-individual variation in thrombus formation all data are
expressed as a percentage of the isotype control. Data are the mean ± S.E. of seven individuals (C and E) and 3 individuals (D). *P < 0.05, **P < 0.005, ***P < 0.0005.
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The inhibitory action of PECAM-1 on collagen induced platelet
activation has been well documented. However, the impact of PE-
CAM-1 activation on platelet response to other agonists has been
less well explored. In this study we conﬁrm the inhibitory effect
of PECAM-1 on GPVI signaling, and go further to show inhibitionof thrombin and ADP induced platelet activation. In line with other
reports PECAM-1 cross-linking exerts a relatively small effect cor-
responding to 5–15% inhibition in platelet function. Similarly var-
iation in the surface expression of PECAM-1 accounted for 6–10% of
the variation in ﬁbrinogen binding and P-selectin expression in re-
sponse to stimulation. To put this into context, we also show that
20–21% of the variation in platelet response to CRP-XL is accounted
3624 C.I. Jones et al. / FEBS Letters 583 (2009) 3618–3624for by variation in the surface expression of GPVI (Table 1). Clearly
the inhibitory effect of PECAM-1 is subtle, and can even be over-
come at the highest concentrations of agonists (Fig. 1B and C:
thrombin 1U/mL, and ADP 104M). However, because PECAM-1
inhibits multiple activation pathways it is likely to be physiologi-
cally important. Therefore during thrombus formation the impact
of PECAM-1 is more substantial than that seen on individual path-
ways in isolation. It is worth noting that, while the two systems are
not strictly analogous, the inhibitory effect on thrombus formation
of cross-linking PECAM-1 was of a similar magnitude to the in-
crease in thrombus formation previously reported in the absence
of PECAM-1 in knock-out mice [17].
The negative relationship between PECAM-1 surface expression
and platelet response to stimuli provides independent conﬁrma-
tion of the physiological effect of PECAM-1. The speciﬁcity of this
negative association between PECAM-1 and platelet responses is
supported by the observation that GPVI and aIIbb3 showed posi-
tive correlations, while GPIa expression did not exhibit any associ-
ation. The magnitude of this PECAM-1 association is similar to that
resulting from variation in GPVI or aIIbb3, and is entirely expected
given that platelet response requires the integration of a large
number of proteins and varies widely throughout the population
[20]. Furthermore, the impact of PECAM-1 on platelet function
may be underestimated in these studies because the reduced
platelet–platelet interaction in ﬂow cytometric assays limits hom-
ophilic ligation.
In conclusion, we have demonstrated that the activation of PE-
CAM-1, through cross-linking, inhibits platelet response to the col-
lagen mimetic, CRP-XL, ADP and thrombin, and have conﬁrmed the
inhibitory action of PECAM-1, by showing an association between
increased surface expression of PECAM-1 and decreased platelet
response. The combination of a relatively small inhibitory effect
on multiple signaling pathways results in a more dramatic inhibi-
tion of thrombus formation than may have been previously
appreciated.
Acknowledgements
This study was supported by the British Heart Foundation (RG/
05/007 and FS/07/018), 6th Framework Programme of the Euro-
pean Union (LSHM-CT-2004-503485) and a grant from the Na-
tional Institute of Health Research of England to SFG and WHO
and the Cambridge Biomedical Research Centre. The authors wish
to thank the staff of the Cambridge BioResource at NHSBT Cam-
bridge for obtaining donor samples and Dr Nicolas Raynal (Depart-
ment of Biochemistry, University of Cambridge) for the CRP-XL.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.febslet.2009.10.037.
References
[1] Muller, W.A., Weigl, S.A., Deng, X. and Phillips, D.M. (1993) PECAM-1 is
required for transendothelial migration of leukocytes. J. Exp. Med. 178, 449–
460.
[2] Chiba, R., Nakagawa, N., Kuroasawa, K., Tanaka, Y., Saito, Y. and Iwamoto, I.
(1999) Ligation of CD31(PECAM-1) on endothelial cells increases adhesivefunction of avb3 integrin and enhances b1 integrin mediated adhesion of
eosinophilis to endothelial cells. Blood 94, 1319–1329.
[3] Piali, L., Albelda, S.M., Baldwin, H.S., Hammel, P., Gisler, R.H. and Imhof, B.A.
(1993) Murine platelet endothelial cell adhesion molecule (PECAM-1/CD31)
modulates b2 integrins on lymphokine-activated killer cells. Eur. J. Immunol.
23, 2464–2471.
[4] Zhao, T.M. and Newman, P.J. (2001) Integrin activation by regulated
dimerization and oligomerization of platelet endothelial cell adhesion
molecule (PECAM)-1 from within the cell. J. Cell Biol. 152, 65–73.
[5] Berman, M.E., Xie, Y. and Muller, W.A. (1996) Roles of platelet endothelial cell
adhesion molecule-1 (PECAM- 1, CD31) in natural killer cell transendothelial
migration and beta(2) integrin activation. J. Immunol. 156, 1515–1524.
[6] Novinska, M.S., Rathore, V., Newman, D.K. and Newman, P.J. (2007) Pecam-1
in: Platelets (Michelson, A.D., Ed.), pp. 221–230, Academic Press.
[7] Cicmil, M., Thomas, J.M., Sage, T., Barry, F.A., Leduc, M., Bon, C. and Gibbins, J.M.
(2000) Collagen, convulxin, and thrombin stimulate aggregation-independent
tyrosine phosphorylation of CD31 in platelets. Evidence for the involvement of
Src family kinases. J. Biol. Chem. 275, 27339–27347.
[8] Edmead, C.E., Crosby, D.A., Southcott, M. and Poole, A.W. (1999) Thrombin
induced association of SHP-2 with multiple tyrosine phosphorylated proteins
in human platelets. FEBS Lett. 459, 27–32.
[9] Sagawa, K., Kimura, T., Swieter, M. and Siraganian, R.P. (1997) The protein-
tyrosine phosphatase SHP-2 associates with tyrosine-phosphorylated
adhesion molecule PECAM-1 (CD31). J. Biol. Chem. 272, 31086–31091.
[10] Jackson, D.E., Kupcho, K.R. and Newman, P.J. (1997) Characterization of
phosphotyrosine binding motifs in the cytoplasmic domain of platelet/
endothelial cell adhesion molecule-1 (PECAM-1) that are required for the
cellular association and activation of the protein-tyrosine phosphatase, SHP-2.
J. Biol. Chem. 272, 24868–24875.
[11] Jackson, D.E., Ward, C.M., Wang, R. and Newman, P.J. (1997) The protein-
tyrosine phosphatase SHP-2 binds platelet/endothelial cell adhesion
molecule-1 (PECAM-1) and forms a distinct signaling complex during
platelet aggregation. J. Biol. Chem. 272, 6986–6993.
[12] Varon, D., Jackson, D.E., Shenkman, B., Dardik, R., Tamarin, I., Savion, N. and
Newman, P. (1998) Platelet/endothelial cell adhesion molecule-1 serves as a
co-stimulatory agonist receptor that modulates integrin dependent adhesion
and aggregation of human platelets. Blood 91, 500–507.
[13] Cicmil, M., Thomas, J.M., Leduc, M., Bon, C. and Gibbins, J.M. (2002) PECAM-1
signalling inhibits the activation of human platelets. Blood 99, 137–144.
[14] Jones, K.L., Hughan, S.C., Dopheide, S.M., Farndale, R.W., Jackson, S.P. and
Jackson, D.E. (2001) Platelet endothelial cell adhesion molecule-1 is a negative
regulator of platelet-collagen interactions. Blood 98, 1456–1463.
[15] Dhanjal, T.S., Ross, E.A., Auger, J.M., McCarty, O.J., Hughes, C.E., Senis, Y.A.,
Buckley, C.D. and Watson, S.P. (2007) Minimal regulation of platelet activity
by PECAM-1. Platelets 18, 56–67.
[16] Patil, S., Newman, D.K. and Newman, P.J. (2001) Platelet endothelial cell
adhesion molecule-1 serves as an inhibitory receptor that modulates platelet
responses to collagen. Blood 97, 1727–1732.
[17] Falati, S. et al. (2006) Platelet PECAM-1 inhibits thrombus formation in vivo.
Blood 107, 535–541.
[18] Wee, J.L. and Jackson, D.E. (2005) The Ig-ITIM superfamily member PECAM-1
regulates the ‘‘outside-in” signaling properties of integrin {alpha}IIb{beta}3 in
platelets. Blood 106, 3816–3823.
[19] Morton, L.F., Hargreaves, P.G., Farndale, R.W., Young, R.D. and Barnes, M.J.
(1995) Integrin alpha 2 beta 1-independent activation of platelets by simple
collagen-like peptides: collagen tertiary (triple-helical) and quaternary
(polymeric) structures are sufﬁcient alone for alpha 2 beta 1-independent
platelet reactivity. Biochem. J. 306, 337–344.
[20] Jones, C.I. et al. (2007) Mapping the platelet proﬁle for functional genomic
studies and demonstration of the effect size of the GP6 locus. J. Thromb.
Haemostasis 5, 1756–1765.
[21] Jones, S. et al. (2008) Peripheral tachykinins and the neurokinin receptor NK1
are required for platelet thrombus formation. Blood 111, 605–612.
[22] Tucker, K. L. et al. (2008). A dual role for integrin linked kinase in platelets:
regulating integrin function and {alpha}-granule secretion. Blood, blood-2008-
03-148502.
[23] De Candia, E., Hall, S.W., Rutella, S., Landolﬁ, R., Andrews, R.K. and De
Cristofaro, R. (2001) Binding of thrombin to glycoprotein Ib accelerates the
hydrolysis of Par-1 on intact platelets. J. Biol. Chem. 276, 4692–4698.
[24] Rathore, V., Stapleton, M.A., Hillery, C.A., Montgomery, R.R., Nichols, T.C.,
Merricks, E.P., Newman, D.K. and Newman, P.J. (2003) PECAM-1 negatively
regulates GPIb/V/IX signaling in murine platelets. Blood 102, 3658–3664.
[25] Jones, C.I. et al. (2009) A functional genomics approach reveals novel
quantitative trait loci associated with platelet signaling pathways. Blood
114, 1405–1416.
